Immunomedics and Seattle Genetics enter into US$2 B Deal for Sacituzumab Govitecan

By Natasha Piper

Pharma Deals Review: Vol 2017 Issue 3 (Table of Contents)

Published: 1 Mar-2017

DOI: 10.3833/pdr.v2017.i3.2227     ISSN: 1756-7874

Section: Licensing



Immunomedics has entered into an exclusive global licence agreement worth up to US$2 B with Seattle Genetics...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details